Psoriasis of the scalp. Extent: Minimum 10% of the total scalp area. Disease severity: Graded as "moderate", "severe" or "very severe" according to the investigator´s global assessment of disease severity. Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs. MedDRA version: 7.0 Level: LLT Classification code 10037157
Conditions
Sponsors
LEO Pharma A/S
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Scalp psoriasis amenable to topical treatment with a maximum of 100 g of medication per week 2. Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs 3. Extent of scalp psoriasis involving more than 10% of the total scalp area 4. Investigator’s assessment of clinical signs of the scalp of at least 2 in one of the clinical signs, erythema, thickness and scaliness, and at least 1 in each of the other two clinical signs 5. Disease severity on the scalp graded as Moderate, Severe or Very Severe according to the investigator’s global assessment of disease severity 6. Patients aged 18 years or above 7. Either sex 8. Any ethnic origin 9. Attending a hospital out-patient clinic, the private practice of a dermatologist or the practice of a general practitioner experienced in the handling of psoriasis vulgaris 10. Following verbal and written information about the trial, the patient must provide signed and dated informed consent before any study related activity is carried out, including washout 11. Patients fulfilling national requirements/law for participation in this study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. PUVA or Grenz ray therapy within 4 weeks prior to randomisation 2. UVB therapy within 2 weeks prior to randomisation 3. Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisation 4. Systemic treatment with all other therapies than biologicals, with a possible effect on scalp psoriasis (e.g., corticosteroids, vitamin D analogues, retinoids, immunosup-pressants) within 4 weeks prior to randomisation 5. Any topical treatment of the scalp (except for medicated shampoos and emollients) within 2 weeks prior to randomisation 6. Topical treatment of the face, trunk and/or limbs with very potent WHO group IV corticosteroids within 2 weeks prior to randomisation 7. Planned initiation of, or changes to concomitant medication that could affect scalp psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the study 8. Current diagnosis of erythrodermic, exfoliative or pustular psoriasis 9. Patients with any of the following conditions present on the scalp area: Viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin 10. Known or suspected abnormality of the calcium homeostasis associated with clinically significant hypercalcaemia 11. Known or suspected severe renal insufficiency or severe hepatic disorders 12. Planned exposure to sun during the study, that may affect scalp psoriasis 13. Known or suspected hypersensitivity to component(s) of the Investigational Products 14. Current participation in any other interventional clinical study 15. Patients who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within a month prior to randomisation 16. Previously randomised and having received at least one treatment application in this study 17. Patients known or suspected of not being able to comply with a trial protocol (e.g., due to alcoholism, drug dependency or psychotic state) 18. Females who are pregnant, or of child-bearing potential and wishing to become pregnant during the study, or are breast feeding 19. Females of child-bearing potential with positive pregnancy test at Visit 1 (all females of child-bearing potential must have a pregnancy test at Visit 1 and should furthermore be willing to use an adequate method of contraception during the study)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the clinical efficacy of once daily treatment for up to 8 weeks of calcipotriol plus betamethasone dipropionate gel with betamethasone dipropionate in the gel vehicle, calcipotriol in the gel vehicle and the gel vehicle alone in patients with scalp psoriasis. ;Secondary Objective: To compare the safety of once daily treatment for up to 8 weeks of calcipotriol plus betamethasone dipropionate gel with betamethasone dipropionate in the gel vehicle, calcipotriol in the gel vehicle and the gel vehicle alone in patients with scalp psoriasis. ;Primary end point(s): Patients with ”Controlled disease” (“Absence of disease” or “Very mild disease”) according to investigator’s global assessment of disease severity at end of treatment. | — |
Countries
Denmark, Spain, Sweden, United Kingdom
Outcome results
None listed